TABLE 1.
Baseline demographic and screening data, as well as pre-treatment baseline measurement of outcome variables and experimental parameters.
| Active (N = 8) |
Control (N = 9) |
|||
| Demographics and Screening | M | SEM | M | SEM |
| Female Subjects | 7 | 4 | ||
| Male Subjects | 1 | 5 | ||
| Age | 21.1 | 2.3 | 21.1 | 3.8 |
| PHQ9 Scorea | 1.9 | 1.6 | 1.9 | 1.9 |
| GAD7 Scoreb | 3.4 | 2.9 | 2.2 | 2.1 |
| HAMD Scorec | 2.4 | 2.3 | 2.1 | 2.1 |
| Subjective Questionnaires | ||||
| SPQd | 21.6 | 4.0 | 22.7 | 3.8 |
| FSQe | 93.9 | 16.0 | 96.9 | 9.4 |
| BAT Behavioralf | ||||
| Steps | 7.3 | 1.3 | 6.4 | 1.5 |
| Anticipation Step g | ||||
| Distress | 61.9 | 24.0 | 62.2 | 22.0 |
| Confidence | 45.9 | 32.0 | 62.8 | 21.0 |
| Final Step h | ||||
| Anticipatory Distress | 66.9 | 28.0 | 69.4 | 24.0 |
| Maximum Distress | 65.9 | 28.0 | 71.1 | 21.0 |
| BAT Physiologic/SCLi | ||||
| Baseline† | 2.91 | 2.70 | 7.99 | 7.30 |
| Anticipation Stepg | 4.63 | 4.20 | 10.70 | 8.30 |
| Final Steph | 7.19 | 5.90 | 12.20 | 9.60 |
| Treatment Parameters | ||||
| Exposures | ||||
| Number completed | 9.5 | 0.9 | 9.3 | 1.1 |
| TMS | ||||
| Time delayk | 16.3 | 4.1 | 14.4 | 3.6 |
| Intensity Toleratedl* | 90.8 | 8.1 | 98.8 | 2.6 |
| Post-TMS Painm | 3.3 | 4.2 | 1.7 | 1.9 |
Statistical testing for baseline comparison performed only on average treatment intensity tolerated and baseline skin conductance level (Mann–Whitney U Test). * indicates significance at p < 0.05 level, †indicates no statistical significance. Other variables were not compared between groups. aPHQ9 score, maximum 27, bGAD7 score, maximum 21, cHAMD score, maximum 52, dSpider Phobia Questionnaire (SPQ) score, maximum 31, eFear of Spiders Questionnaire (FSQ) score, maximum 126, fBehavioral measures examined during Behavioral Avoidance Test (BAT), gMeasures examined during anticipation step of BAT, hMeasures examined during the last step each individual subject completed during both pre and post-treatment BATs, referred to as the final step or final common step, iPhysiologic measure, skin conductance level (SCL) as examined during the BAT, kMinute delay from the end of the exposure treatment to the initiation of TMS treatment, lMaximum intensity tolerated by subjects during TMS (as% of motor threshold), mPost-TMS discomfort experienced by subjects as rated on the short-form McGill scale, maximum 45.